MicroRNA-646 inhibits proliferation and cell cycle progression of nasopharyngeal carcinoma cells by targeting mTOR

Y-L Song1, M-Z Pan, A-L Wang

  • 1Department of Otolaryngology, The Seventh People's Hospital of Jinan, Jinan, China. 13953190521@163.com.

Abstract

Insights

MicroRNA-646 is downregulated in nasopharyngeal carcinoma and inhibits tumor growth by targeting mTOR. Upregulating microRNA-646 can suppress cancer cell proliferation and progression, offering a potential therapeutic strategy for nasopharyngeal carcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Nasopharyngeal carcinoma (NPC) is a prevalent cancer in certain regions.
  • Understanding the molecular mechanisms regulating NPC progression is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the role of microRNA-646 (miR-646) in regulating the proliferation and cell cycle of nasopharyngeal carcinoma cells.
  • To determine if miR-646 targets the mammalian target of rapamycin (mTOR) pathway in NPC.

Main Methods:

  • Quantitative Real-time polymerase chain reaction (qRT-PCR) to assess miR-646 and mTOR expression.
  • Cell counting kit-8 (CCK-8) assay and flow cytometry to evaluate proliferation and cell cycle.
  • Dual-luciferase reporter gene assay and Pearson correlation analysis to confirm the miR-646-mTOR interaction.
  • Gain-of-function experiments to elucidate miR-646's regulatory role.

Main Results:

  • MicroRNA-646 was significantly downregulated in NPC tissues and cell lines.
  • Low miR-646 expression correlated with poorer survival in NPC patients.
  • Overexpression of miR-646 inhibited NPC cell proliferation and induced cell cycle arrest.
  • miR-646 directly targets mTOR, which was found to be upregulated in NPC.
  • mTOR overexpression reversed the inhibitory effects of miR-646.

Conclusions:

  • MicroRNA-646 acts as a tumor suppressor in nasopharyngeal carcinoma.
  • miR-646 inhibits NPC cell proliferation and cell cycle progression by targeting mTOR.
  • Restoring miR-646 levels may represent a therapeutic strategy for NPC.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K